MX2012005849A - Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d. - Google Patents
Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d.Info
- Publication number
- MX2012005849A MX2012005849A MX2012005849A MX2012005849A MX2012005849A MX 2012005849 A MX2012005849 A MX 2012005849A MX 2012005849 A MX2012005849 A MX 2012005849A MX 2012005849 A MX2012005849 A MX 2012005849A MX 2012005849 A MX2012005849 A MX 2012005849A
- Authority
- MX
- Mexico
- Prior art keywords
- vitamin
- sensitivity
- tumor cells
- restoration
- immunomodulatory compounds
- Prior art date
Links
- 229940046008 vitamin d Drugs 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 230000035945 sensitivity Effects 0.000 title abstract 2
- 210000004881 tumor cell Anatomy 0.000 title abstract 2
- 229930003316 Vitamin D Natural products 0.000 abstract 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 3
- 235000019166 vitamin D Nutrition 0.000 abstract 3
- 239000011710 vitamin D Substances 0.000 abstract 3
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26406209P | 2009-11-24 | 2009-11-24 | |
| US32447310P | 2010-04-15 | 2010-04-15 | |
| PCT/US2010/057951 WO2011066351A1 (en) | 2009-11-24 | 2010-11-24 | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012005849A true MX2012005849A (es) | 2012-08-23 |
Family
ID=44066895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012005849A MX2012005849A (es) | 2009-11-24 | 2010-11-24 | Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d. |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8841325B2 (https=) |
| EP (1) | EP2504703B1 (https=) |
| JP (2) | JP2013512195A (https=) |
| CA (1) | CA2780998C (https=) |
| MX (1) | MX2012005849A (https=) |
| WO (1) | WO2011066351A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| WO2011066351A1 (en) * | 2009-11-24 | 2011-06-03 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
| CN111205268B (zh) * | 2014-10-30 | 2021-01-26 | 康朴生物医药技术（上海）有限公司 | 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| CN102342938B (zh) * | 2002-05-17 | 2014-08-20 | 细胞基因公司 | 用于治疗和控制实体瘤的方法及组合物 |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| WO2005016872A1 (en) | 2003-06-11 | 2005-02-24 | Novacea, Inc. | Treatment of lung cancer with active vitamin d compounds in combination with other treatments |
| US20060078494A1 (en) * | 2004-09-24 | 2006-04-13 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| PL2068874T3 (pl) * | 2006-08-07 | 2015-06-30 | Abbvie Biotherapeutics Inc | Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1 |
| RU2536242C2 (ru) * | 2007-09-28 | 2014-12-20 | Антродженезис Корпорейшн | Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров |
| WO2010104588A2 (en) * | 2009-03-10 | 2010-09-16 | The Johns Hopkins University | Compositions and methods for characterizing and treating neoplasia |
| WO2011066351A1 (en) * | 2009-11-24 | 2011-06-03 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
-
2010
- 2010-11-24 WO PCT/US2010/057951 patent/WO2011066351A1/en not_active Ceased
- 2010-11-24 JP JP2012540169A patent/JP2013512195A/ja not_active Withdrawn
- 2010-11-24 MX MX2012005849A patent/MX2012005849A/es active IP Right Grant
- 2010-11-24 CA CA2780998A patent/CA2780998C/en not_active Expired - Fee Related
- 2010-11-24 EP EP10833897.1A patent/EP2504703B1/en not_active Not-in-force
- 2010-11-24 US US13/511,002 patent/US8841325B2/en not_active Expired - Fee Related
-
2014
- 2014-08-12 US US14/457,825 patent/US20150283124A1/en not_active Abandoned
-
2015
- 2015-05-19 JP JP2015101583A patent/JP5839637B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2504703A4 (en) | 2013-05-08 |
| JP2015145432A (ja) | 2015-08-13 |
| EP2504703B1 (en) | 2016-11-16 |
| EP2504703A1 (en) | 2012-10-03 |
| CA2780998A1 (en) | 2011-06-03 |
| US8841325B2 (en) | 2014-09-23 |
| WO2011066351A1 (en) | 2011-06-03 |
| US20150283124A1 (en) | 2015-10-08 |
| JP2013512195A (ja) | 2013-04-11 |
| US20130171196A1 (en) | 2013-07-04 |
| CA2780998C (en) | 2016-07-12 |
| JP5839637B2 (ja) | 2016-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
| IN2012DN02735A (https=) | ||
| IN2012DN02702A (https=) | ||
| IN2012DN00754A (https=) | ||
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| MY160456A (en) | Benzodiazepine bromodomain inhibitor | |
| PH12017500930A1 (en) | Hsp90 inhibitor combinations | |
| CL2007002316A1 (es) | Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer. | |
| SG10201811480WA (en) | Therapeutic compounds and compositions | |
| BR112012024019A2 (pt) | forma de dosagem de liberação controlada, e, método para liberar uma droga | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| MX2009012690A (es) | Composiciones, metodos, dispositivos y sistemas para el cuidado bucal. | |
| CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| PH12014501639B1 (en) | Pharmaceutical compositions and methods | |
| BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
| PH12015501088A1 (en) | Dimeric compounds | |
| MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
| BR112012022243A8 (pt) | Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico | |
| MX2010002667A (es) | Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3. | |
| MX2019015527A (es) | Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. | |
| CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
| WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |